Xbrane's Q2 PnL came in slightly ahead of our expectations, but the report reinforces the case's central risk: without an October FDA approval for Lucamzi, the SEK60m Fenja loan maturing in January 2027 has no clear repayment source. The market read the report neutrally, and the stock now screens as "Fairly priced" compared to the weighted fair value.
LÄS MER
